Startseite
Kongressberichte 2021
ESMO Congress 2021
Monday, September 20
Mini oral sessions
NETs and endocrine tumours
NETs and endocrine tumours
LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Jaume Capdevila, et al.
Conclusions
At the final analysis of COSMIC-311 with longer follow-up, C maintained its superior efficacy vs P with a manageable safety profile in pts with previously treated RAIR-DTC. The PFS benefit was consistent with the interim analysis and irrespective of prior VEGFR-targeted therapy.
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Sophie Leboulleux, et al.
Conclusions
Trametinib in RAS-mutated patients restores RAI uptake in a few patients and is followed by tumor response in 20% with limited adverse events. (PHRC 2015, NCT 03244956).
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Jorge Hernando, et al.
Conclusions
In the DUNE heavily pretreated population, sensitivity to systemic therapies after progression on D+T overcomes the expected PFS2, especially in high grade NENs. This finding opens a new potential study concept of sequential therapies, including immunotherapy, in advanced NENs.
1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Halfdan Sorbye, et al.
Conclusions
We performed a comprehensive assessment of the molecular tumour alterations in a large series of gastroenteropancreatic high-grade neuroendocrine neoplasms. We found few RB1 mutations and a marked difference in the molecular profile compared to prior results in SCLC and LCLC, challenging the use of SCLC as a paradigm for GEP-NEC. We found a quite similar profile comparing large-cell and small-cell GEP-NEC, but a profile variation according to primary tumour site and suggest a possible molecular strategy to separate NEC from NET G3. Our study shows a very high fraction of GEP-NEC with targetable mutations, pointing to novel important therapeutic strategies.
1101MO - Development of CAR T-cells for future treatment of NETs
Barbara Mandriani, et al.
Conclusions
Anti-SSTR CAR T cells exert antitumor activity against SSTR+ NET cell lines, both in vitro and in vivo.